Bristol-Myers Squibb, CEO Giovanni Caforio, told CNBC on Friday that the company is "a step closer to creating the big company" after the shareholders greenlit a $ 74 billion acquisition of Celgene.
"It's really the value of the deal is the pipeline. We are talking about five pipeline assets, potential launches over the next two years. In fact, three of these drugs have been filed with the FDA since the beginning of the year. So we've made great progress already, confirming our thesis. "
Shares in Bristol-Myers and Celgene climbed both Friday morning after the vote, but both ended the season in the red. Bristol-Myers closed more than 1
" I'm focused, and we're focused on creating long-term value, and we're going to work on the integration, "Caforio said." When we start working together, we have an opportunity to start new drugs right away. I believe the value of the new company will be demonstrated quickly. "